Lysosomal degradation of PD-L1 is associated with immune-related adverse events during anti-PD-L1 immunotherapy in NSCLC patients.
Kashiwada T, Takano R, Ando F, Kuroda S, Miyabe Y, Owada R, Miyanaga A, Asatsuma-Okumura T, Hashiguchi M, Kanazawa Y, Yoshida H, Seike M, Gemma A, Iwai Y.
Kashiwada T, et al. Among authors: yoshida h.
Front Pharmacol. 2024 May 10;15:1384733. doi: 10.3389/fphar.2024.1384733. eCollection 2024.
Front Pharmacol. 2024.
PMID: 38799168
Free PMC article.